Companies
Cytek Biosciences
the Cytek Borealis, a new seven-laser spectral flow cytometry system unveiled in 2026, extends full-spectrum detection depth for high-parameter immunophenotyping panels.
- Country
- United States
- Ticker
- NASDAQ:CTKB
NASDAQ:CTKB
Commercial
Coverage
| CN | EU | US | |
|---|---|---|---|
| analytics-pat | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | $44.1 million for the quarter ended March 31, 2026 | marketscreener.com |
| Production site | Fremont, California; Wuxi, China; Seattle, Washington; and Singapore | marketscreener.com |
| Regulatory approval | Northern Lights-CLC system received CE Marking (2020) and is registered in the European Union (2023) and China (Class II) | marketscreener.com |
| Revenue | $201.5 million for 2025 | bccresearch.com |
| Headcount | 702 employees | bccresearch.com |
Independent sources: bccresearch.com · marketscreener.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Flow cytometers for bioproduction | analytics-pat | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.